Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeneDx Holdings Equity Warrant Exp 22 July 2026 WGSWW

Financial Services
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing... see more

Recent & Breaking News (NDAQ:WGSWW)

Sema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 Guidance

GlobeNewswire January 9, 2023

Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire December 30, 2022

New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU

GlobeNewswire December 5, 2022

Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction

GlobeNewswire November 14, 2022

FINAL DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses of $100,000 to Contact the Firm

Accesswire November 7, 2022

24-Hour Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 6, 2022

3-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 4, 2022

Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022

GlobeNewswire November 4, 2022

4-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 3, 2022

5-Day Deadline Alert: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire November 2, 2022

Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies

GlobeNewswire October 31, 2022

Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns

GlobeNewswire October 27, 2022

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire October 26, 2022

Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels

GlobeNewswire October 26, 2022

ROSEN, Global Investor Counsel, Encourages Sema4 Holdings Corp. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - SMFR, SMFRW

Newsfile October 13, 2022

Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders

GlobeNewswire October 13, 2022

Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study

GlobeNewswire October 5, 2022

FINAL DEADLINE APPROACHING: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. With Losses to Contact the Firm

Accesswire October 4, 2022

SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses to Contact the Firm

Accesswire October 3, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sema4 Holdings Corp. - SMFR; SMFRW

Newsfile September 23, 2022